Chronic pulmonary insufficiency after surgery
Conditions
Interventions
Group A :After surgery, intravenous injection of 40mg of parecoxib + tizanidine placebo (2ml of saline)
Group B :After the procedure, intravenous injection of flurbiprofen axetil 50mg + tizoxapine placebo (2ml of normal saline)
Group C :After the procedure, administer 40mg of parecoxib and 1mg of tizanidine via intravenous injection
Group D :After the procedure, administer an intravenous injection of 50mg of flurbiprofen axetil and 1mg of tizanidine
Sponsors
Shanghai East Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years, any gender; 2. ASA classification I-II; 3. BMI 18.5-30 kg/m^2; 4. Elective laparoscopic cholecystectomy under general anesthesia; 5. Voluntarily participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergic to opioids, parecoxib, flurbiprofen ester, or any study drug; 2. Severe heart, lung, liver, or kidney dysfunction; 3. History of gastrointestinal ulcers or bleeding; 4. Long-term use of opioids or history of drug abuse; 5. Pregnant or breastfeeding women; 6. Cognitive impairment or mental illness, unable to cooperate with pain assessment; 7. Intraoperative conversion to open surgery or occurrence of severe complications requiring ICU admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24h composite benefit endpoint success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| NRS scores at rest/on coughing and AUC;Total rescue analgesic consumption;Time to first flatus;Incidence of PONV;30-day readmission rate; | — |
Countries
China
Contacts
Public ContactJunyan Yao
Shanghai East Hospital
Outcome results
None listed